Navigation Links
Pharmasset Reports Fiscal Year End 2011 Financial Results
Date:11/14/2011

PRINCETON, N.J., Nov. 14, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal year ended September 30, 2011. At fiscal year end Pharmasset held $166.5 million in cash and cash equivalents and used $21.7 million of our cash and cash equivalents during the fourth quarter of fiscal 2011.

Pipeline Update and 2011 HighlightsPSI-7977The recently-announced registrational program for PSI-7977, the once-a-day nucleotide analog for hepatitis C virus (HCV) infection, is the first to pursue an interferon-free, all-oral regimen, and the first to include patients with all HCV genotypes (GT). The three core studies will evaluate the all-oral two-drug combination of PSI-7977 and ribavirin (RBV) administered for 12 weeks.

The first trial, FISSION, is a pivotal study of PSI-7977 with RBV for 12 weeks in approximately 500 patients with HCV GT2 or GT3. FISSION is designed to demonstrate the superiority of PSI-7977/RBV over the current standard-of-care for HCV GT2/3, pegylated interferon (Peg-IFN) and ribavirin for 24 weeks. The second Phase 3 trial, POSITRON, is planned to begin in early 2012. POSITRON will enroll approximately 225 patients with HCV GT2 or GT3 who cannot take interferon, thus supporting a placebo comparator arm for this trial. During the first quarter of 2012, data from ongoing open-label assessments of PSI-7977/RBV in subjects with HCV GT1 in ELECTRON and QUANTUM will be reviewed and incorporated into the final design for the third registrational trial, NEUTRINO. This trial will also investigate a 12-week regimen of PSI-7977/RBV versus a placebo comparator, and will enroll approximately 280 patients with HCV regardless of viral genotype, inclu
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
5. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
10. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
11. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 ... Production Market by Product (Equipment, Consumables), by Type (Monoclonal, ... Diagnostic Labs, Research Institutes) - Analysis & Global ... studies the global Antibody Production Market for the ... is expected to reach $2.572 Billion by 2019 ...
(Date:4/30/2015)... Spirax Sarco, the leader in product ... announce that for the first time in the company’s ... a Queen’s Award for Innovation – the UK’s highest ... of a unique flowmeter. , The Spirax Sarco ... steam flow measurement. The device provides reliable, accurate ...
(Date:4/30/2015)... --  Tamir Biotechnology , a leading developer of RNA ... antiviral therapy program. Clinical Progress ... evaluated and considered by a number of clinicians on ... first quarter of 2015, the company participated in the ... of Potential Treatments and Vaccines For Ebola In West ...
(Date:4/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), an ... has commenced an underwritten public offering of its common ... a 30-day option to purchase up to an additional ... in the public offering. The offering is subject to ... to whether or when the offering may be completed, ...
Breaking Biology Technology:Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... VoIP (voice over internet protocol) has been a long time ... have been nervously looking over our shoulder as VoIP technology ... first greeted it with a confident snicker or brash statements ... work, they dont understand Telephony! But time passed and Telephonys ...
... topics of this newsletter hit a nerve as sharply as social ... on this topic than I seem to receive on all other ... things get a little lonely in my office.) , ,Last week, ... fundamental sense." , ,I said, "The value is in actively ...
... The MIT Club of Wisconsin is recognizing nPoint, ... technological innovation. nPoint, a Madison-based provider of motion devices ... of three winners of the annual 2004 MIT Club ... Club of Wisconsin consists of alumni of the Massachusetts ...
Cached Biology Technology:A telecom person in an VoIP world 2Social networks: Readers respond 2Social networks: Readers respond 3Social networks: Readers respond 4
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... endometrium (uterine lining) and transplanted into the brains of ... of brain cells damaged by the disease, according to ... The findings are published in the ... are preliminary results, the findings increase the likelihood that ...
... NEW YORK (May 6, 2010) The Wildlife ... of a large, "landscape-wide" conservation approach to protect globally ... study looked at wildlife populations in northern Republic of ... national park, a community-managed reserve, and various logging concessions. ...
... produced the first whole genome sequence of the 3 billion ... that up to 2 percent of the DNA in the ... or in Neanderthals, ancestors. The international research ... Institute (NHGRI), part of the National Institutes of Health, reports ...
Cached Biology News:Endometrial stem cells could repair brain cells damaged by Parkinson's disease 2Study looks at gorillas, elephants and logging in Congo 2Study looks at gorillas, elephants and logging in Congo 3Complete Neanderthal genome sequenced 2Complete Neanderthal genome sequenced 3Complete Neanderthal genome sequenced 4Complete Neanderthal genome sequenced 5
Request Info...
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
...
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: